Quality od life in patients with psoriasis vulgaris during the COVID 19 pandemic

Abstract

Background: Psoriasis is a chronic inflammatory dermatological disease that has a major impact on quality of life. Skin diseases are the most common somatic causes of psychological disorders and, conversely, under the influence of a psychological disorder, there is usually a cutaneous manifestation. This is the main reason for conducting this research during the COVID-19 pandemic, a time when most of the population is under constant stress. The research is aimed at determining the quality of life of patients with psoriasis. Materials and Methods: In this research, we employed two questionnaires. One collected particulars such as the patient's age and gender. The other was a DLQI (Dermatological Life Quality Index) questionnaire. Due to the epidemiological situation, the questionnaire was completed by patients who came for a control examination, and most of them were contacted by phone; some completed the questionnaires online. One hundred six respondents participated actively in this research. Results: The lowest score of the Dermatological Life Quality Index (DLQI) is 3, and the highest is 29. The most commonly received scores were 4 and 8, among which the score of 4 was given to 19 (17.9%) respondents and the score of 8 was given to 21 (19.8%) respondents. 69.8% of the respondents experienced problems with the affected parts of the skin rated as answers "moderately" or "a lot." In terms of health issues, female respondents had lower values than male respondents. However, by applying the t-test to determine the statistical significance of the difference with p ≤ 0.05, the value of t was determined to be-0.48 (p = 0.31), which means that there was no statistically significant difference. Conclusion: When compared to the results of studies performed several years ago, together with this study performed during the COVID-19 pandemic, there are no major differences in terms of quality of life in patients with psoriasis.

Psoriasis worsening related to COVID-19 vaccination: Report from a single-center

“…Psoriasis is a chronic inflammatory skin condition that may be triggered by stress, certain medications, and infections, including COVID-19 [3][4][5]. However, the association between vaccination and the worsening of psoriasis has been reported mainly after vaccines against influenza (H1N1), pneumococcal pneumonia, and yellow fever [6].…”

“…There are certainly possible cutaneous adverse reactions of COVID vaccination, including urticaria, morbilliform rash, pityriasis rosea, and the exacerbation of pre-existing dermatoses [1,2]. Psoriasis is a chronic cutaneous inflammatory condition that may be triggered by stress, certain drugs, infection, including COVID-19, and less commonly, vaccines [3][4][5][6][7][8][9][10].…”